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ABSTRACT Modulation of the cholinergic neurotrans-
mitter system results in changes in memory performance,
including working memory (WM), in animals and in patients
with Alzheimer disease. To identify associated changes in the
functional brain response, we studied performance measures
and regional cerebral blood flow (rCBF) using positron
emission tomography (PET) in healthy subjects during per-
formance of a WM task. Eight control subjects received an
infusion of saline throughout the study and 13 experimental
subjects received a saline infusion for the first 2 scans followed
by a continuous infusion of physostigmine, an acetylcholines-
terase inhibitor, for the subsequent 8 scans. rCBF was mea-
sured using H215O and PET in a sequence of 10 PET scans that
alternated between rest and task scans. During task scans,
subjects performed the WM task for faces. Physostigmine both
improved WM efficiency, as indicated by faster reaction times,
and reduced WM task-related activity in anterior and poste-
rior regions of right midfrontal gyrus, a region shown pre-
viously to be associated with WM. Furthermore, the magni-
tudes of physostigmine-induced change in reaction time and
right midfrontal rCBF correlated. These results suggest that
enhancement of cholinergic function can improve processing
efficiency and thus reduce the effort required to perform a
WM task, and that activation of right prefrontal cortex is
associated with task effort.
Working memory (WM) refers to processes that maintain
temporary, active representations of information so that they
are available for further processing or recall (1, 2). The
cholinergic neurotransmitter system is associated with WM,
insofar as cholinergic agonists improve performance (3–5) and
antagonists impair performance (6, 7) on WM tasks. Phy-
sostigmine, an acetylcholinesterase inhibitor that increases the
duration of action of acetylcholine at the synapse, also im-
proves performance on WM tasks in animals and in patients
with Alzheimer disease (3–5, 8, 9).
Functional brain imaging studies of humans have identi-
fied brain regions involved in the performance of object and
spatial WM tasks, including occipital, temporal, parietal, and
prefrontal cortical areas (10–13). On object WM tasks,
functional imaging studies in humans, as well as lesion and
single neuron recording studies in nonhuman primates,
indicate that posterior occipitotemporal cortex is associated
more with perceptual processing, whereas prefrontal cortex
is associated more with maintaining an active representation
of the stimulus after it has been removed from view (10,
14–17). Although it has been shown that cholinergic mod-
ulation alters WM performance, the site of modulation in the
distributed neural system that mediates WM has yet to be
determined. Therefore, we decided to investigate changes in
regional cerebral blood f low (rCBF) and behavioral perfor-
mance (reaction time) associated with cholinergic stimula-
tion during a WM task.
MATERIALS AND METHODS
Twenty-one right-handed healthy volunteers participated in
the study. Each participant gave written informed consent
after the purpose of the study and risks involved were ex-
plained (as approved by National Institute on Agingy
Institutional Review Board). The control and experimental
groups did not differ in mean age, years of education, or gender
distribution (Table 1).
rCBF was measured using H215O and positron emission
tomography (PET) in a sequence of 10 PET scans that
alternated between rest and task scans. Subjects were asked to
remain awake during rest scans with their eyes open and ears
unplugged. During task scans, subjects performed the WM
task for faces (10). Stimuli were presented in three squares of
equal size, one centered above two positioned side by side.
Each item began with a 4 sec presentation of a face to
remember in the upper square; followed by a 6 sec delay
consisting of a 1 sec interstimulus interval, a 4 sec presentation
of the three square stimulus array each containing a gray
square, and another 1 sec interstimulus interval. After the
delay, two test faces were presented for 4 sec, one in each of
the lower two squares, and subjects indicated which test face
matched the face presented at the beginning of the item by
pressing a button with the right or left thumb. Faces used were
novel for each trial.
Control subjects received an infusion of saline throughout
the study. Experimental subjects received saline infusion for
the first two scans; a loading dose of physostigmine was
administered before the third scan at a rate of 1.93 mgyhr for
10 min, followed by a maintenance solution that continued
to completion of the study at the rate of 0.816 mgyhr, for a
total dose of 1 mgyhr of physostigmine. Blood samples were
taken after each scan to assess physostigmine levels. High
performance liquid chromatography assay of plasma phy-
sostigmine concentration was performed. Heart rate and
blood pressure were monitored continuously during drug
infusion. To reduce the potential of side effects, 0.2 mg of the
peripheral cholinergic antagonist glycopyrrolate was admin-
istered (18, 19).
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Using statistical parametric mapping (20) PET data were
registered to correct between scan movement, spatially
normalized to the orientation, size, and shape of the Ta-
lairach and Tournoux (21) atlas brain, and smoothed with a
20 mm 3 20 mm 3 12 mm Gaussian filter. Within- and
between- group comparisons were performed on rCBF data
that were adjusted with analysis of covariance to correct for
differences in whole brain CBF. Statistical significance (P ,
0.05) was determined based on the spatial extent of contig-
uous volumes of rCBF change (22). Local maxima within
areas of significant change were defined as voxels with Z
scores that exceeded the values for all voxels within a 18
mm 3 18 mm 3 20 mm volume centered on that voxel (23).
Data from scans 3 through 10 were analyzed separately for
both groups to identify the brain regions that were activated
during task performance off and on drug, and to identify the
brain regions that demonstrated drug-related alterations of
activation, as demonstrated by an interaction between drug
and task conditions. Within-group changes in task-related
rCBF increases, comparing data from the first two scans to
data from the subsequent eight scans in the drug group, were
analyzed to corroborate findings from the between group
analysis of the effect of physostigmine.
RESULTS
During PET studies with drug, the mean plasma concentration
of physostigmine remained relatively stable with a slight but
significant increase over time [F(7,84) 5 9.89, P , 0.0001]. All
mean physostigmine concentrations ranged between 2.2 and
2.9 ngyml; the mean increase in plasma concentration was 0.67
ngyml.
Reaction time (RT) improved progressively across scans
during physostigmine infusion in experimental subjects
[F(4,48) 5 6.06, P , 0.0005], whereas RT did not change over
time for control subjects (F , 1). Groups did not differ in RT
before drug infusion (F , 1). Accuracy was above 90% on all
task scans in both groups.
Patterns of rCBF increase during the WM task as com-
pared with rest, on scans 3–10, are shown in Fig. 1 for the off
FIG. 1. For each comparison, the figure shows the result projected onto the right hemisphere and indicates the location for the three coronal
sections in frontal cortex, located 112, 124, and 136 mm anterior to the anterior commissure. Z scores that exceeded a threshold of 2.33 (P 5
0.01, two-tailed, before correction for multiple comparisons based on spatial extent) and obtained significance after an analysis of spatial extent
are shown. Significant rCBF increases during WM task performance relative to rest for scans 3–10 are shown for the control and physostigmine
groups. The group x task interaction shows greater task-related rCBF increases during saline infusion as compared with physostigmine infusion
on comparable scans.
Table 1. Subject demographics
Control
(n 5 8)
Physostigmine*
(n 5 13)
Age (yr 6 SD) 37 6 15 48 6 20
Education (yr 6 SD) 16 6 3 17 6 2
Gender 6Fy2M 5Fy8M
*Groups did not differ significantly.
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and on drug conditions, as well as the group comparison of
activations.
For control subjects, rCBF increases were observed in a
large region of primary visual and visual extrastriate cortex
extending from the medial occipital lobe into bilateral ventral
occipitotemporal and right parietal cortex and a region of right
prefrontal cortex, including posterior, inferior, and midfrontal
regions. Two areas of significant rCBF increase during WM
task performance relative to rest for scans 3–10 were found
(Fig. 1, Control): bilateral posterior cortex (volume 5 159.9
cm3, P , 0.001) with local maxima in primary visual cortex
[Brodmann Area (BA) 17; 6, 2102, 0], bilateral ventral
occipitotemporal cortex (BA 19; 32, 264, 220; 236, 272,
220), left medial occipital cortex (BA 18; 24, 290, 212), and
right parietal cortex (BA 7; 26, 264, 36); and right prefrontal
cortex (volume 5 23.3 cm3, P , 0.001) with local maxima in
the posterior midfrontal gyrus (BA 45; 38, 20, 24) and anterior
midfrontal gyrus (BA 9; 34, 34, 36). The right prefrontal
activation extended into the inferior frontal gyrus, but no local
maxima were found there.
Performance of the WM task during physostigmine infu-
sion similarly was associated with activation in posterior
cortical areas, and with a smaller activation in right prefron-
tal cortex. In the experimental group, two areas of significant
rCBF increase during WM task performance relative to rest
on scans 3–10 were found (Fig. 1, Physostigmine): bilateral
posterior cortex (volume 5 149.7 cm3, P , 0.001) with local
maxima in primary visual cortex (BA 17; 26, 2100, 212; 12,
292, 28); and right prefrontal cortex (volume 5 4.4 cm3, P ,
0.05) with local maxima in the posterior midfrontal gyrus
(BA 45; 32, 12, 20) and inferior frontal gyrus (BA 44; 32, 12,
4). Unlike the control subject results, the activation did not
extend into the anterior midfrontal gyrus. A right parietal
area was seen in the experimental group, corresponding to
that seen in the control group, but was not of sufficient
spatial extent to achieve statistical significance based on our
criteria.
The group x task interaction (Fig. 1), showing greater
task-related rCBF increases during saline infusion as com-
pared with physostigmine infusion on comparable scans, in-
dicated that the right ventral region of inferior temporaly
cerebellar cortex (volume 5 6.1 cm3; P , 0.01; local maxima:
44, 260, 224; 26, 250, 228; 20, 242, 220), as well as a large
area of right prefrontal cortex (volume 5 12.6 cm3, P , 0.0001)
with local maxima both in posterior (BA 44; 48, 8, 16; 26, 16,
36; 48, 18, 32) and anterior (BA 9; 28, 38, 36; 36, 50, 20) regions
in the midfrontal gyrus, were less activated during physostig-
mine infusion as compared with saline infusion. No significant
region with smaller rCBF increases on saline infusion was
found.
Mean rCBF values for the right prefrontal region in the
midfrontal gyrus (BA 9y44), which demonstrated a significant
group x task interaction are presented in Fig. 2 and show that
infusion of physostigmine alters rCBF in this region only when
it is participating in WM performance and not at rest
[F(3,202)5 6.62, P , 0.0003]. Prior to infusion, rCBF values
for control subjects and experimental subjects did not differ
significantly, and both groups showed similar task-related
rCBF increases (P . 0.1 for main effects of group and task and
for their interaction). During the WM task, the control subjects
showed a rCBF response that was significantly higher than that
seen in the drug group [F(1,57) 5 64.5; P , 0.0001]. Subjects
in the physostigmine group showed no change in rCBF from
rest to task in this same right midfrontal region (P . 0.1),
which showed almost no overlap with the right inferior frontal
region that was activated. No difference was observed in
resting state rCBF [P . 0.1 for main effects of group (drug vs.
control) and time (pre- vs. post-infusion) and for their inter-
action].
A direct, within-group comparison of rCBF during the
WM task on drug (scans 3–10) to rCBF during the WM task
off drug (scans 1 and 2) in the experimental subjects
confirmed the difference seen between the experimental and
control groups in the right prefrontal region but not in the
right anterior extrastriate region. Task-related right prefron-
tal rCBF increases were significantly reduced during phy-
sostigmine administration in a region that included the
anterior midfrontal gyrus as well as inferior frontal and
anterior cingulate cortex. Moreover, the magnitude of the
reduction correlated significantly with the decrease in RT
(r 5 0.57, P , 0.05) during physostigmine infusion (Fig. 3),
indicating that greater improvements in RT were associated
with larger reductions in right prefrontal rCBF. The mag-
nitudes represent differences between the RT and rCBF
measures (using the local maximum from the within-group
analysis of drug effect on task; 20, 20, 28) during the first
WM task PET scan, obtained in the absence of drug, and the
final WM task PET scan, obtained during physostigmine
infusion. Because no region in right extrastriate cortex was
seen that demonstrated within-group changes in task-related
rCBF increases corresponding to that seen in the group by
task interaction, this remains a suggestive but less robust
finding. No significant change in rCBF was observed in the
control group (no drug) with comparable subtractions.
DISCUSSION
The results of this study show that enhancement of cholin-
ergic neurotransmission results in an improvement in WM
efficiency that is correlated with an alteration of brain
activity in a cortical region known to play a central role in
WM. Moreover, this local alteration in brain activity is
evident only during performance of the WM task and not at
rest. Cholinergic agents affect memory function in animals
and humans. For example, tacrine, a long-acting acetylcho-
linesterase inhibitor, is used clinically to treat cognitive
symptoms of Alzheimer disease. The brain mechanism by
which tacrine improves cognitive performance is unknown.
For the first time, however, we have demonstrated a cho-
linergically induced modulation of functional brain response
FIG. 2. The group x task interaction for mean rCBF values from the
right prefrontal region that showed a significant group difference in
the size of task-related rCBF increases (Fig. 1), is shown.
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to a memory task that was related to the observed improve-
ment in behavior.
Previous work also has shown that cholinergic enhancement
using physostigmine does not affect resting rCBF in healthy
human subjects (24), although in patients with Alzheimer
disease, resting rCBF in hypometabolic cortical regions is
increased by physostigmine (24, 25). In a previous PET study,
the dopaminergic agonist, apomorphine, was found to impair
memory performance and diminish memory task-related
rCBF increases in prefrontal cortex (26).
Given that acetylcholinesterase inhibitors prolong acetyl-
choline activity at the synapse, one might expect improve-
ment in performance to be associated with increased rCBF
in a task-specific brain region, yet we observed a reduction
in right prefrontal rCBF. One possible explanation is that
reduced activation in right prefrontal cortex may ref lect the
shorter time required to perform the WM task, although
several papers, including a recent functional magnetic res-
onance imaging study, indicate that right prefrontal activity
is associated more with maintenance of an active represen-
tation over the memory delay than with response selection
(10, 14–17).
The observed reduction of right prefrontal activity might
have been a direct effect of physostigmine. Anatomically, the
synaptic circuitry of cholinergic prefrontal fibers includes
symmetric synapses on pyramidal cells (27); symmetric synap-
tic morphology is characteristic of inhibitory mechanisms
(28–30). It is unclear, however, why a direct inhibition of right
prefrontal activity would be correlated with improved WM
performance. Moreover, direct inhibition demands neuronal
activity and therefore may result in increased rather than
decreased cerebral blood flow.
An alternative explanation for the physostigmine-induced
reduction of the right prefrontal rCBF response is that right
prefrontal activity is associated with the effort needed to
perform the WM task, and that this region is recruited as the
effort required to perform the task increases. Prefrontal
cortex may become more active with tasks that require a
greater allocation of attentional resources (31). A PET study
of word list recall showed that increased memory load
resulted in greater rCBF increases in frontal cortex as well
as in other brain structures (32). Another PET study showed
that increases in the difficulty of a face-matching task
increased rCBF in the right midfrontal gyrus with a local
maximum 6 mm from one of the anterior local maxima
identified in this study (33). Similarly, studies of event-
related electrophysiological potentials show that the re-
sponse amplitude in the prefrontal cortex increases with task
difficulty during WM (34, 35). The anticholinesterase effects
of physostigmine may enhance efficiency of WM processes,
thus reducing the effort required to perform the task and the
need to recruit prefrontal cortex. The mechanism by which
physostigmine reduces effortful processing during WM re-
mains unclear. Physostigmine may enhance efficiency by
amplifying processing of information in the focus of atten-
tion (36) or by minimizing the effects of distracting stimuli
(35).
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